Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide

Evelien Zonneveld-Huijssoon, Sarah T A Roord, Wilco de Jager, Mark Klein, Salvatore Albani, Stephen M Anderton, Wietse Kuis, Femke van Wijk, Berent J Prakken

Research output: Contribution to journalArticlepeer-review

Abstract

Mucosal immune therapy with disease-inducing antigens is an effective way to prevent experimental arthritis, but in humans these antigens are unknown. In juvenile idiopathic arthritis, however, T cell recognition of a so-called bystander antigen, heat shock protein 60 (HSP60), is associated with a good prognosis. Recently epitopes derived from HSP60, a microbial peptide (p1) and its self-homologue (p2) were reported to induce tolerogenic T cell responses in vitro in patients with arthritis. A study was undertaken to determine whether mucosal administration of these bystander epitopes can be similarly effective in suppressing arthritis.
Original languageEnglish
Pages (from-to)2199-206
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume70
Issue number12
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide'. Together they form a unique fingerprint.

Cite this